Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.31 |
| ▸ | MTOR | P42345 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29697727 | 0.78 | HRH4 (0.34) | — | |
| SCHEMBL24580208 | 0.78 | HRH4 (0.34) | — | |
| SCHEMBL26612701 | 0.78 | HRH4 (0.34) | — | |
| SCHEMBL28487072 | 0.77 | — | — | |
| SCHEMBL26122612 | 0.76 | KRAS (0.34) | PIK3CAMTOR | |
| SCHEMBL26122602 | 0.76 | KRAS (0.34) | PIK3CAMTOR | |
| SCHEMBL26528236 | 0.74 | HTR6 (0.52) | HTR6PIK3CAMTOR | |
| SCHEMBL19637232 | 0.73 | NUDT1 (0.33) | — | |
| SCHEMBL23841610 | 0.73 | — | — | |
| SCHEMBL23206634 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | HTR6 4691/4885PIK3CA 36/4885MTOR 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.